Hovione increases oral dosage production capacity22 Oct 2018
‘One Site Shop’ expands to respond to growing demands.
Hovione plans to increase production capacity in oral dosage forms in Portugal, to strengthen the integrated offering. New commercial-scale equipment for blending, tableting and coating will complement existing small-scale development equipment. This decision to expand follows growing customer demand since, one year ago Hovione started offering end-to-end solutions, from drug substance to drug product, from the Loures site.
Hovione's ‘One Site Shop’ allows customers to streamline their supply chain, reduce time to market and benefit from seamless project management. This increase in capacity will help Hovione customers to consistently bring products faster to market.
“Hovione has a unique value proposition when it comes to processing amorphous solid dispersions. Our company has more than 15 years of experience in pharmaceutical spray drying and has produced hundreds of batches for clinical trials and commercial supplies. Our customers now see drug product manufacturing at the site where they produce their drug product intermediate as a natural extension of the range of value-added services they expect from us. They want to keep their product in the same capable hands. This investment shows our commitment to listen to our customers and continue to support their evolving needs,” says Frédéric Kahn Vice-President of Marketing & Sales at Hovione.
In parallel, by the end of 2018, Hovione will be completing the qualification of its continuous tableting line at Hovione New Jersey, which will enable the site to offer end-to-end solutions for US customers that are keen to keep their supply chain local.
The capacity expansion program started in 2016 and will continue in the coming 5 years. In the first 2 years, Hovione has relocated its development services to a new centre with 7,000 m2 in Lisbon, fully equipped with the most recent tools where Hovione is able to handle potent and highly potent compounds. Globally within its R&D Hovione added new labs, new drug product centres, pilot plants and a state-of-the-art particle engineering technologies both in the US and in PT. Locally, the Loures site expanded its drug substance reaction vessel capacity with a small-scale production area and a new pilot plant. The company also installed more spray drying capacity at the site and started the operation of a new drug product centre equipped with oral dosage form and inhalation manufacturing capabilities. In New Jersey, Hovione doubled the size of its development and manufacturing operations. In Cork, Hovione also expanded its chemical synthesis capacity devoted to contract manufacturing.
Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic
10 Sep 2019
Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered NSCLC and thyroid cancer patients who may be suitable for Lilly's RET inhibitor.Read more
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development
10 Sep 2019
Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.Read more
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market
9 Sep 2019
Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.Read more
Catalent to open new clinical supply facility in San Diego
6 Sep 2019
Will enhance speed to clinic through expanded early-phase clinical supply and oral dose development services.Read more
Take part in pharma’s largest reputation survey
6 Sep 2019
Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.Read more
BioCity backs world's first Rx to OTC switch incubator
5 Sep 2019
Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.Read more
Velesco Pharma to triple its clinical manufacturing capacity
4 Sep 2019
Company's new building in Wixom, MI replace and consolidate its existing manufacturing site in Kalamazoo, MI.Read more
Taiwan's biggest CDMO secures FDA approval
3 Sep 2019
Customers claim Bora's oral solid dosage Zhunan facility is in the top 5 external manufacturing facilities they’ve ever visited in the world.Read more
China relaxes import regulations to improve access and availability of affordable medicines
3 Sep 2019
The potential for generics to support the healthcare needs of China is significant.Read more
Dutch company receives €20 million for skin cancer diagnostic test
3 Sep 2019
The test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove lymph nodes.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation